▁Introduction 10.375
: 6.515625
<0x0A> 3.947265625
In 4.578125
▁a 2.931640625
▁notable 8.25
▁development 2.76953125
▁in 1.6640625
▁the 0.63818359375
▁fight 3.173828125
▁against 0.3017578125
▁cancer 5.0390625
, 0.1962890625
▁British 5.55859375
▁bi 4.74609375
ote 0.35302734375
ch 0.53173828125
▁firm 1.1669921875
, 3.056640625
▁yet 13.03125
▁to 0.38818359375
▁be 0.53564453125
▁named 1.1982421875
, 0.260498046875
▁has 0.64697265625
▁released 6.3671875
▁encourag 7.14453125
ing 0.003170013427734375
▁early 2.986328125
- 2.3359375
stage 0.1302490234375
▁results 1.3857421875
▁for 1.8447265625
▁a 1.123046875
▁ground 5.703125
bre 0.44287109375
aking 0.00115203857421875
▁cancer 2.2734375
▁drug 1.5888671875
. 1.2802734375
▁However 6.86328125
, 0.042755126953125
▁c 8.9140625
aut 0.147705078125
ious 0.02752685546875
▁voices 5.4921875
▁in 3.447265625
▁the 0.11309814453125
▁industry 1.4326171875
▁are 1.6484375
▁rem 6.53515625
inding 0.0247344970703125
▁us 1.451171875
▁that 0.53515625
▁further 5.1875
▁tests 3.6640625
▁and 2.240234375
▁tri 1.337890625
als 0.0010232925415039062
▁are 0.52392578125
▁necessary 2.0625
▁before 0.828125
▁definit 7.1640625
ive 0.2008056640625
▁conclus 1.1064453125
ions 0.0019664764404296875
▁can 0.265625
▁be 0.00555419921875
▁drawn 0.619140625
. 0.4130859375
▁The 3.013671875
▁potential 5.3828125
▁of 2.0625
▁this 1.3466796875
▁drug 0.658203125
▁to 1.8525390625
▁provide 4.6484375
▁new 3.01953125
▁hope 0.6728515625
▁to 0.99951171875
▁cancer 0.74658203125
▁patients 0.15966796875
▁makes 7.171875
▁it 0.64208984375
▁an 2.255859375
▁exc 1.587890625
iting 0.00017082691192626953
▁prospect 1.3505859375
, 1.1201171875
▁but 0.7158203125
▁exper 5.37890625
ts 0.00014901161193847656
▁are 1.3935546875
▁ur 2.373046875
ging 0.005596160888671875
▁vig 6.625
il 0.0194244384765625
ance 0.0218963623046875
▁and 1.99609375
▁careful 4.13671875
▁evaluation 2.40625
▁before 1.6064453125
▁celebr 6.24609375
ating 0.343505859375
▁any 3.173828125
▁potential 4.0390625
▁break 1.630859375
through 0.00351715087890625
s 1.6435546875
. 0.177734375
<0x0A> 0.273193359375
Body 10.3125
: 3.908203125
<0x0A> 2.849609375
1 5.71875
. 0.76318359375
▁Ex 5.94140625
c 1.3564453125
iting 0.0904541015625
▁Promise 7.5390625
▁from 4.37109375
▁Initial 5.3125
▁Tri 2.189453125
als 0.26171875
: 3.666015625
<0x0A> 0.2232666015625
Acc 3.91015625
ording 0.01151275634765625
▁to 0.003322601318359375
▁the 1.1826171875
▁British 3.232421875
▁bi 1.3115234375
ote 0.006366729736328125
ch 0.08795166015625
▁company 1.865234375
, 0.44921875
▁the 1.2841796875
▁pre 5.5234375
lim 0.2362060546875
inary 0.0018444061279296875
▁find 2.806640625
ings 2.300739288330078e-05
▁from 0.94482421875
▁initial 3.00390625
▁clin 1.8232421875
ical 0.0019063949584960938
▁tri 0.1527099609375
als 7.641315460205078e-05
▁of 1.7353515625
▁their 2.763671875
▁innov 4.3828125
ative 0.0232086181640625
▁cancer 0.69873046875
▁drug 0.2122802734375
▁appear 5.52734375
▁to 0.359130859375
▁be 1.087890625
▁highly 3.546875
▁prom 0.5478515625
ising 0.00015306472778320312
. 0.317138671875
▁These 4.7265625
▁early 1.9814453125
▁results 1.5478515625
▁suggest 2.0390625
▁that 0.172607421875
▁the 0.449462890625
▁drug 0.333740234375
▁may 1.6376953125
▁have 1.79296875
▁the 0.76904296875
▁potential 0.210693359375
▁to 0.0264434814453125
▁significantly 2.287109375
▁improve 1.142578125
▁treatment 4.09375
▁options 2.09375
▁for 0.1209716796875
▁a 2.357421875
▁range 1.541015625
▁of 0.00234222412109375
▁cancer 1.9501953125
▁types 0.72802734375
▁by 4.71875
▁target 2.15234375
ing 0.0032978057861328125
▁specific 2.28125
▁signal 5.9140625
ing 0.0748291015625
▁path 0.1258544921875
ways 0.002300262451171875
▁within 3.841796875
▁the 0.8515625
▁cells 2.45703125
, 2.69921875
▁in 3.787109375
hib 1.6591796875
iting 0.0029048919677734375
▁the 1.44921875
▁growth 0.6748046875
▁and 1.3505859375
▁spread 0.258544921875
▁of 0.11309814453125
▁cancer 0.49853515625
ous 1.6484375
▁cells 0.429931640625
. 0.88232421875
▁If 4.27734375
▁successful 2.525390625
, 0.164306640625
▁this 0.7412109375
▁ground 2.97265625
bre 0.0716552734375
aking 0.00011706352233886719
▁medic 5.53515625
ation 0.0135498046875
▁could 0.43115234375
▁change 4.03125
▁the 0.10321044921875
▁landscape 2.38671875
▁of 0.1451416015625
▁cancer 0.1741943359375
▁treatment 0.293212890625
. 2.2578125
<0x0A> 0.21044921875
2 0.328125
. 0.0025691986083984375
▁Ca 2.896484375
ution 0.0287628173828125
ary 0.86962890625
▁Analysis 7.1484375
: 0.630859375
<0x0A> 0.00853729248046875
Des 2.3984375
p 0.0007877349853515625
ite 7.152557373046875e-05
▁the 0.56201171875
▁initial 3.302734375
▁excitement 2.888671875
, 1.119140625
▁anal 4.08203125
yst 0.022216796875
s 0.0016193389892578125
▁are 0.9970703125
▁emphas 6.484375
izing 0.0205841064453125
▁the 0.73779296875
▁importance 1.4404296875
▁of 0.008392333984375
▁proceed 7.07421875
ing 0.0009341239929199219
▁with 0.205078125
▁ca 0.06622314453125
ution 6.413459777832031e-05
. 1.4912109375
▁They 1.91015625
▁stress 3.935546875
▁the 0.76123046875
▁need 0.455810546875
▁for 0.1680908203125
▁further 0.45361328125
▁investig 5.71484375
ations 0.0151214599609375
, 2.658203125
▁including 1.3759765625
▁additional 2.51953125
▁clin 0.7138671875
ical 0.0005927085876464844
▁tri 0.09442138671875
als 6.9141387939453125e-06
▁involving 6.1015625
▁larger 0.6328125
▁patient 0.955078125
▁coh 3.3671875
ort 1.3113021850585938e-05
s 0.0008778572082519531
, 0.57568359375
▁to 1.13671875
▁assess 3.693359375
▁the 0.1748046875
▁drug 0.71533203125
' 0.02679443359375
s 0.0005664825439453125
▁safety 1.8984375
▁and 0.1483154296875
▁effic 0.428466796875
acy 1.1801719665527344e-05
. 1.267578125
▁Conc 8.7265625
ern 0.00032401084899902344
s 0.055084228515625
▁have 1.2529296875
▁also 0.76953125
▁been 0.032440185546875
▁raised 0.05718994140625
▁regarding 2.03125
▁potential 2.833984375
▁side 0.29248046875
▁effects 0.0239715576171875
▁and 1.6015625
▁the 1.642578125
▁drug 1.0205078125
' 0.007007598876953125
s 0.00026535987854003906
▁limitations 6.765625
▁in 1.11328125
▁tre 0.82861328125
ating 1.0609626770019531e-05
▁specific 2.26953125
▁cancer 1.8125
▁stra 8.703125
ins 0.0002856254577636719
. 0.290771484375
▁This 4.2578125
▁measured 12.53125
▁response 2.263671875
▁serves 5.71484375
▁as 0.158203125
▁a 0.321533203125
▁rem 0.321044921875
inder 5.8770179748535156e-05
▁that 0.47412109375
▁medical 5.4453125
▁break 1.2802734375
through 0.00020647048950195312
s 0.0013055801391601562
▁often 3.205078125
▁require 1.0224609375
▁persistent 10.078125
▁efforts 3.20703125
▁and 0.95166015625
▁met 5.703125
icul 4.1365623474121094e-05
ous 0.0035228729248046875
▁scr 3.9453125
ut 9.608268737792969e-05
iny 0.005779266357421875
. 1.5634765625
<0x0A> 0.1728515625
3 0.869140625
. 0.0021495819091796875
▁Address 8.3203125
ing 0.0307464599609375
▁Pot 4.953125
ential 0.0019350051879882812
▁Ch 2.333984375
alleng 0.0006628036499023438
es 0.0003204345703125
: 0.06646728515625
<0x0A> 0.0011157989501953125
Bi 7.01171875
ote 0.046844482421875
chn 2.1796875
ology 0.053863525390625
▁exper 2.4609375
ts 1.33514404296875e-05
▁assert 7.4375
▁that 0.037994384765625
▁the 1.150390625
▁long 5.203125
▁road 2.1484375
▁from 4.69140625
▁initial 0.978515625
▁testing 3.271484375
▁to 0.090576171875
▁successful 4.69921875
▁commercial 1.7734375
ization 0.11865234375
▁is 1.529296875
▁often 2.75
▁fra 1.2177734375
ug 0.00012385845184326172
ht 0.00011742115020751953
▁with 0.0014429092407226562
▁challeng 0.794921875
es 0.0013256072998046875
. 0.83251953125
▁These 2.830078125
▁hur 4.7109375
d 9.775161743164062e-06
les 0.0004963874816894531
▁include 0.75927734375
▁rig 5.3984375
orous 0.00879669189453125
▁regul 1.01171875
atory 0.000255584716796875
▁appro 0.95166015625
val 4.184246063232422e-05
s 1.0888671875
, 0.58740234375
▁scr 8.7890625
ut 0.0013332366943359375
iny 0.2200927734375
▁from 0.50048828125
▁the 1.43359375
▁scientific 3.009765625
▁community 0.05633544921875
, 0.22119140625
▁and 0.185302734375
▁the 1.587890625
▁need 0.85009765625
▁for 0.457275390625
▁substantial 4.3203125
▁invest 1.0029296875
ments 1.0400390625
▁to 2.380859375
▁support 2.185546875
▁compreh 7.75390625
ensive 0.00020778179168701172
▁clin 0.8955078125
ical 0.0006384849548339844
▁tri 0.1343994140625
als 2.0742416381835938e-05
. 0.1981201171875
▁Furthermore 5.25
, 0.0003802776336669922
▁un 5.125
for 0.6591796875
ese 0.0017375946044921875
en 0.00794219970703125
▁comp 2.322265625
lications 0.0009984970092773438
▁can 1.8369140625
▁arise 0.479736328125
▁during 0.81103515625
▁later 4.34765625
▁stages 0.6357421875
▁of 0.11297607421875
▁drug 2.03515625
▁development 0.06689453125
, 0.5380859375
▁prompt 5.5078125
ing 0.000637054443359375
▁the 1.783203125
▁need 0.1507568359375
▁for 0.07269287109375
▁adjust 7.00390625
ments 0.1373291015625
▁or 2.90625
▁re 3.7578125
ass 3.22265625
ess 0.017791748046875
ment 0.8876953125
. 1.3037109375
▁Despite 2.77734375
▁the 1.7626953125
▁enthus 7.93359375
ias 0.037109375
m 5.328655242919922e-05
▁surrounding 0.671875
▁the 1.5400390625
▁drug 1.6142578125
' 0.293701171875
s 0.00206756591796875
▁potential 0.6611328125
, 0.51513671875
▁industry 4.578125
▁watch 4.33984375
ers 0.0452880859375
▁stress 2.630859375
▁that 1.73828125
▁p 6.33203125
atience 0.043121337890625
, 3.330078125
▁dil 2.439453125
ig 0.0058441162109375
ence 4.696846008300781e-05
, 0.1595458984375
▁and 0.01447296142578125
▁additional 8.5703125
▁evidence 5.9765625
▁are 0.51513671875
▁cru 3.36328125
cial 0.0006985664367675781
▁to 1.1201171875
▁adv 5.6171875
ancement 4.32421875
. 1.1279296875
<0x0A> 0.07940673828125
4 1.2548828125
. 0.0018558502197265625
▁Pot 3.857421875
ential 0.01404571533203125
▁Imp 1.7861328125
act 0.417236328125
▁on 0.71044921875
▁Can 2.236328125
cer 0.0009012222290039062
▁Tre 0.9072265625
at 0.00025773048400878906
ment 0.071044921875
: 0.11285400390625
<0x0A> 0.0016412734985351562
If 4.08984375
▁the 2.654296875
▁British 5.40625
▁bi 0.07525634765625
ote 0.0005707740783691406
ch 0.06170654296875
▁firm 1.09765625
' 0.85400390625
s 0.002201080322265625
▁cancer 3.34765625
▁drug 0.161865234375
▁passes 5.44921875
▁further 2.662109375
▁rig 5.109375
orous 0.0016040802001953125
▁testing 0.9443359375
▁and 1.0859375
▁obtain 6.84765625
s 0.0034637451171875
▁regul 0.646484375
atory 4.76837158203125e-05
▁appro 0.04132080078125
val 3.159046173095703e-05
, 0.35400390625
▁the 3.541015625
▁imp 2.072265625
lications 0.01424407958984375
▁for 1.107421875
▁cancer 0.2724609375
▁treatment 0.337158203125
▁could 0.75
▁be 0.01971435546875
▁enorm 3.609375
ous 0.0007696151733398438
. 0.02398681640625
▁Research 4.2890625
ers 0.35791015625
▁believe 1.869140625
▁that 0.280517578125
▁specifically 10.578125
▁target 0.2276611328125
ed 0.80029296875
▁dru 1.888671875
gs 8.821487426757812e-06
▁have 4.328125
▁the 0.201904296875
▁potential 0.0205841064453125
▁not 7.53515625
▁only 0.030029296875
▁to 0.004444122314453125
▁improve 0.734375
▁patients 4.2109375
' 0.00566864013671875
▁ch 4.30078125
ances 0.00015342235565185547
▁for 3.013671875
▁surv 0.5703125
ival 0.0230560302734375
▁but 0.45556640625
▁also 0.0811767578125
▁to 0.10858154296875
▁minim 4.70703125
ize 0.0008034706115722656
▁har 7.02734375
sh 0.91943359375
▁side 0.222412109375
▁effects 0.0078887939453125
▁often 5.3828125
▁associated 0.15771484375
▁with 0.0002639293670654297
▁conventional 1.431640625
▁treat 1.333984375
ments 7.748603820800781e-06
▁like 5.15234375
▁chem 0.1253662109375
other 0.0130157470703125
apy 0.006671905517578125
▁and 1.6025390625
▁radiation 0.12127685546875
▁ther 0.329833984375
apy 0.01483917236328125
. 0.01922607421875
▁Still 6.9453125
, 0.0860595703125
▁this 3.296875
▁new 2.365234375
▁drug 1.150390625
▁must 2.0703125
▁be 1.4990234375
▁subject 3.208984375
ed 0.1500244140625
▁to 0.00421142578125
▁extensive 2.26953125
▁research 4.59765625
, 3.3359375
▁clin 3.119140625
ical 0.0018138885498046875
▁tri 0.08538818359375
als 1.239776611328125e-05
, 0.048095703125
▁and 0.022369384765625
▁peer 5.046875
▁reviews 2.21484375
▁before 0.366455078125
▁it 0.94091796875
▁can 0.37890625
▁real 8.3203125
ist 0.002166748046875
ically 4.172325134277344e-05
▁be 0.8623046875
▁incorpor 3.90625
ated 4.029273986816406e-05
▁into 0.021942138671875
▁standard 2.0078125
▁cancer 0.48095703125
▁treatment 0.59326171875
▁practices 2.91015625
. 0.0736083984375
<0x0A> 0.2486572265625
5 0.91259765625
. 0.001987457275390625
▁Indust 6.4609375
ry 0.0045623779296875
▁Imp 3.05859375
lications 0.51708984375
: 0.052520751953125
<0x0A> 0.001277923583984375
The 1.12109375
▁success 3.669921875
▁of 0.311279296875
▁this 0.44775390625
▁British 3.1953125
▁bi 0.1552734375
ote 0.00036835670471191406
ch 0.029998779296875
▁firm 0.453857421875
' 0.1820068359375
s 0.0003604888916015625
▁drug 1.90625
▁could 1.7314453125
▁significantly 3.443359375
▁impact 0.97314453125
▁the 0.486083984375
▁bi 6.76171875
ote 0.128173828125
chn 0.55615234375
ology 0.0072479248046875
▁and 3.044921875
▁ph 0.150390625
arma 0.000335693359375
ce 0.00206756591796875
ut 5.9604644775390625e-06
ical 6.830692291259766e-05
▁indust 0.16650390625
ries 4.410743713378906e-06
▁at 6.21484375
▁large 0.01291656494140625
. 0.1568603515625
▁If 2.322265625
▁the 1.0009765625
▁drug 0.43212890625
▁proves 0.7275390625
▁successful 2.845703125
▁in 0.84228515625
▁later 3.8984375
▁stages 0.78125
▁of 0.0211334228515625
▁development 1.87109375
, 0.1865234375
▁it 0.57666015625
▁may 2.630859375
▁p 2.83984375
ave 0.0009260177612304688
▁the 0.006504058837890625
▁way 0.0049285888671875
▁for 0.0119476318359375
▁other 1.861328125
▁similar 2.107421875
▁target 5.96484375
ed 0.014404296875
▁ther 1.3291015625
ap 0.00492095947265625
ies 3.0994415283203125e-06
▁to 2.119140625
▁gain 4.82421875
▁cred 7.56640625
ibility 0.251708984375
▁and 1.1474609375
▁invest 8.203125
or 1.0263671875
▁interest 2.24609375
. 0.1363525390625
▁This 2.298828125
, 5.21484375
▁in 0.039581298828125
▁turn 0.00305938720703125
, 0.003025054931640625
▁could 0.252197265625
▁lead 1.7958984375
▁to 0.00879669189453125
▁further 2.638671875
▁adv 1.6025390625
anc 0.304931640625
ements 1.5854835510253906e-05
▁in 0.1898193359375
▁tre 4.90234375
ating 0.00010836124420166016
▁various 2.734375
▁dise 2.947265625
ases 0.0001341104507446289
, 1.2685546875
▁not 5.39453125
▁just 1.40625
▁cancer 0.11285400390625
. 0.367431640625
▁However 2.611328125
, 0.0017061233520507812
▁with 4.5234375
▁the 1.9150390625
▁potential 2.10546875
▁for 0.6455078125
▁immense 7.5390625
▁financial 3.38671875
▁gain 2.212890625
, 1.0751953125
▁anal 5.31640625
yst 0.00036263465881347656
s 0.0009284019470214844
▁warn 1.431640625
▁against 1.810546875
▁hast 2.966796875
y 0.112060546875
▁conclus 1.1845703125
ions 8.547306060791016e-05
▁or 2.193359375
▁infl 7.9453125
ated 0.031768798828125
▁expect 0.1513671875
ations 2.2292137145996094e-05
, 3.005859375
▁stress 4.96875
ing 0.0007219314575195312
▁the 0.4248046875
▁importance 1.23046875
▁of 0.00441741943359375
▁maintain 5.8984375
ing 0.00016236305236816406
▁object 4.60546875
ivity 0.004947662353515625
▁and 0.51416015625
▁prior 6.6875
it 0.001514434814453125
izing 0.003692626953125
▁patient 2.58203125
▁safety 0.36328125
▁and 3.041015625
▁well 1.7568359375
- 0.21240234375
be 0.0006003379821777344
ing 5.53131103515625e-05
. 0.73388671875
<0x0A> 0.08380126953125
Con 5.38671875
clusion 0.34033203125
: 0.1949462890625
<0x0A> 3.08984375
As 3.505859375
▁British 4.72265625
▁bi 0.0430908203125
ote 0.0004565715789794922
ch 0.11151123046875
▁research 6.49609375
ers 0.2220458984375
▁report 5.65625
▁prom 2.029296875
ising 4.315376281738281e-05
▁results 1.998046875
▁in 3.29296875
▁early 1.51171875
- 0.8369140625
stage 0.0137176513671875
▁tri 1.23828125
als 4.971027374267578e-05
▁for 1.1494140625
▁a 0.441650390625
▁ground 0.66162109375
bre 0.01922607421875
aking 1.2874603271484375e-05
▁cancer 0.2437744140625
▁drug 0.169921875
, 0.02056884765625
▁industry 2.25
▁exper 0.59130859375
ts 7.510185241699219e-06
▁and 5.78515625
▁anal 1.8408203125
yst 0.00023829936981201172
s 0.0001569986343383789
▁ins 7.81640625
ist 0.002899169921875
▁on 1.517578125
▁maintain 3.24609375
ing 4.9233436584472656e-05
▁a 1.0322265625
▁level 2.36328125
- 0.90576171875
head 0.00153350830078125
ed 0.0192718505859375
▁approach 0.37744140625
. 1.9521484375
▁Though 4.7890625
▁the 1.1591796875
▁potential 1.5537109375
▁to 3.92578125
▁revolution 2.384765625
ize 0.0012540817260742188
▁cancer 0.487548828125
▁treatment 0.15380859375
▁is 0.72412109375
▁und 1.7724609375
ou 3.025390625
bt 0.00131988525390625
edly 0.05780029296875
▁exc 0.52490234375
iting 3.7789344787597656e-05
, 0.0156402587890625
▁ca 0.953125
ution 0.0039005279541015625
▁prev 8.2109375
ails 0.0009703636169433594
. 1.896484375
▁R 4.640625
ig 0.32568359375
orous 0.0072784423828125
▁testing 1.419921875
, 1.79296875
▁repeat 8.7734375
able 3.609375
▁results 2.177734375
, 0.03814697265625
▁and 0.050445556640625
▁extensive 3.49609375
▁tri 5.15625
als 0.0034503936767578125
▁are 0.458251953125
▁necessary 0.6396484375
▁to 1.3779296875
▁confirm 2.583984375
▁the 0.84423828125
▁drug 0.4736328125
' 0.01065826416015625
s 0.002185821533203125
▁effic 1.3994140625
acy 7.271766662597656e-06
▁and 0.47705078125
▁safety 0.498046875
▁before 0.90869140625
▁it 1.6640625
▁can 0.32861328125
▁become 2.91796875
▁a 0.99267578125
▁vi 2.0859375
able 3.719329833984375e-05
▁treatment 1.765625
▁option 0.026397705078125
. 0.96484375
▁While 3.78125
▁optim 3.59765625
ism 0.211181640625
▁is 1.52734375
▁encourag 3.08203125
ed 1.8857421875
, 0.0928955078125
▁it 2.43359375
▁is 0.90673828125
▁inc 6.890625
umb 0.00020420551300048828
ent 0.00032258033752441406
▁upon 0.322265625
▁everyone 3.345703125
▁involved 0.5302734375
▁to 0.662109375
▁temper 4.15234375
▁expect 1.19140625
ations 0.0001252889633178711
, 2.583984375
▁ens 5.97265625
uring 0.0003409385681152344
▁that 0.380859375
▁patient 3.544921875
▁well 2.962890625
- 0.10174560546875
be 0.0003120899200439453
ing 0.00017404556274414062
▁remains 1.4609375
▁the 1.94921875
▁driving 5.140625
▁force 0.1611328125
▁behind 0.278564453125
▁these 4.421875
▁scientific 5.4765625
▁adv 0.90380859375
anc 0.133056640625
ements 6.151199340820312e-05
. 0.037200927734375
